Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Borealis-1: Apatorsen in Advanced Transitional Cell Carcinoma
NCT01454089Phase 2Completed
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2011
- Primary completion
- Nov 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
A Phase 2 trial of apatorsen in transitional cell carcinoma (TCC), sponsored by Achieve Life Sciences. Started Oct 2011; status: completed.
02
Drugs
apatorsen
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT01454089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01454089.